MATCH results: implications for the internist

Area of Science:

• Cardiology
• Neurology
• Clinical Trials

Background:

• Antiplatelet therapy is crucial for secondary stroke prevention.
• Combination antiplatelet therapy has shown promise but requires careful evaluation.
• Previous studies like ESPS-2 demonstrated benefits of combined therapy.

Purpose of the Study:

• To evaluate the safety and efficacy of clopidogrel plus aspirin for secondary stroke prevention.
• To assess the benefit of dual antiplatelet therapy in high-risk patients with recent transient ischemic attack (TIA) or ischemic stroke.

Main Methods:

• The Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study was a large-scale clinical trial.
• Patients with recent TIA or ischemic stroke were treated with clopidogrel alone or clopidogrel plus aspirin.

Main Results:

• Adding aspirin to clopidogrel did not provide a statistically significant greater reduction in stroke risk compared to clopidogrel monotherapy.
• The combination therapy was associated with a significant increase in life-threatening bleeding complications.
• The MATCH study did not replicate the positive findings of ESPS-2 regarding dual antiplatelet therapy.

Conclusions:

• Clopidogrel plus aspirin is not recommended for secondary stroke prevention in patients with a history of ischemic stroke or TIA at this time.
• The increased risk of severe bleeding outweighs the potential modest benefit in this patient population.
• Further research may be needed to identify optimal antiplatelet strategies for high-risk stroke patients.